At the top of the wish list of the biotech companies and the whole world is of course the vaccine that would halt the pandemic. However, for the biotech sector, the prospects are obviously wider. From antivirals to specific therapies, the opportunities are not lacking and in the context of the pandemic, the market seems to have understood it quickly.
The numbers on the other hand do not lie. The initial public offerings (IPOs) that accompany the companies’ entry on the stock exchange mark a new record. And with the regulated markets, new direct investments by specialized entities, starting with venture capital, are flourishing. The party, in short, has just started and given the circumstances promises to last a long time.
If you want to be the first to find the latest discoveries in the biotech sector and why the companies that entered the race to find a vaccine against COVID-19 are doing so well, download for free the Born2Invest mobile app. Find the latest business news and stay on top of the market.
Wall Street discovers the biotech fever
The world of biotech is in turmoil like never before, a recent Business Insider survey suggested. According to data released in August by Dealogic, in the course of 2020, the initial public offerings in the U.S. market would have already reached a total value of $9.4 billion, breaking, several months in advance, the previous annual record set in 2018.
And that’s not all: on the first day of stock market presence, companies would have posted an average increase of 34%. That is a sign that the enthusiasm of investors far outstrips previous valuations.
The connection between the biotech sector and the medical one
The link between the biotech sector and the medical sector has been impressively strengthened over the years thanks to the development of three areas: biopharmaceuticals, diagnostics, and vaccines. Since the beginning of the 1980s, Assobiotec Federchimica recalled, the therapies supported by biotechnology have affected over 350 million patients worldwide. Currently, reported the same association, “about 50% of all new drugs and therapies in development for the near future are biotech and the proportion is growing in innovative treatments such as vaccines, monoclonal antibodies for the treatment of tumors and inflammatory/infectious diseases, cell therapies, gene therapy, and regenerative medicine.”
In this context, the race for vaccine and coronavirus treatments has helped to attract strong investor interest. “The expectation that the industry can provide one or more therapeutic solutions to the COVID-19 pandemic has acted as a catalyst for the growth of biotech stocks on the stock exchange,” reported, in June, the U.S. company Clarivate’s BioWorld specialized portal and data provider.
At that time, the specific indicator developed by the Philadelphia-based company itself – the BioWorld Biopharmaceutical Index – jumped 36% year-on-year from -4.6% in the overall Wall Street index, the Dow Jones Industrial Average. The big price spike recorded on the stock market since the end of March was decisive, even to say the least.
Since the beginning of April, the biotech pharmaceutical sector has been booming on the global stock market, outperforming its US counterpart (Nasdaq Biotech) and, above all, the general Wall Street index.
Billions invested in the biotech sector
The USA remains the epicenter of financing but the boom in the sector is a global phenomenon. In August, there were 49 Ipo’s in world markets with total investments of $12.22 billion. A record, of course. As many as 29 stock market debuts were recorded between June and July, attracting $8.7 billion in newborn public companies.
On June 16th, the U.S. Royalty Pharma plc was listed in New York with a transaction of almost $2.2 billion. Among other debuts with a huge investment are the $799 million raised by SK Biopharmaceuticals for its entry into the Korean stock exchange and the nearly $600 million raked by Danish Ascendis Pharma in July. $345 million were raised from the stock offering of Vir Biotechnology, a San Francisco-based company currently developing a vaccine against the new coronavirus.
Initial public offerings, in any case, represent only a minority share of investments in the sector. Again according to Bioworld, the sum of all capital contribution transactions for the sector – both for listed companies and private companies – exceeds $81 billion in 2020. And yes, it seems superfluous to add this, but this too is a record.
Not only the pandemic influences the growth of the biotech sector
To feed the fortunes of biotech companies, however, there is not only the Covid factor. Last year, the sector had recorded the maximum purchase of the bioscience & nutrition branch of the US company DuPont by its compatriot International Flavors & Fragrances. A transaction worth more than $26 billion that had turned the spotlight on a growing market.
By 2024, according to a Deloitte report, global prescription sales are expected to reach $1.18 trillion, with a compound annual growth rate of nearly 7 percent over the period. It is plausible, at this point, to assume that the current pandemic may lead analysts to upwardly adjust their estimates.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in valori, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [uMobix Affiliate Program Review]
This week, we're covering everything from hustle culture to spying on kids, making this affiliate digest look like it has...
Stanford University Returns Millions from FTX
Between November 2021 and May 2022, Bankman directed donations of more than €5.5 million from FTX Group to Stanford University....
Biova Project Launched an Equity Crowdfunding Campaign on Mamacrowd
Biova Project makes deals with players in large-scale distribution and production to recover, store, and transform unsold food, or food...
Novo Nordisk Plans to Open a Tech Headquarters in Spain
Novo Nordisk increased its profit by 42.5% in the first half of 2023, reaching 39,242 million Danish crowns (€5.26 million)....
Immorente Invest Maintains its Financial Stability
Although the occupancy rate has fallen from 92% to 90.2% compared with the end of 2022, the company expects this...
Biotech1 week ago
Asabys Partners Leads a €14 Million Round in Gradient Denervation
Markets2 weeks ago
Markets Are Looking Iffy, but That’s Seasonal
Biotech4 days ago
Vertex Obtains EMA Validation to Expand Indications for Kaftrio
Crowdfunding1 week ago
58 Crowdinvesting Platforms Authorized Under the New Regulation in Europe